Credit Suisse Cuts Alnylam (ALNY) PT to $50, Keeps 'Outperform'

October 6, 2016 7:23 AM EDT
Get Alerts ALNY Hot Sheet
Price: $38.96 -0.31%

Rating Summary:
    13 Buy, 7 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade ALNY Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Credit Suisse analyst Alethia Young cut her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $50.00 (from $145.00) but maintained an Outperform after the company announced termination of revusiran.

Young commented, "Lowering TP to $50/sh due to concerns about broader implications to the platform, but we still see value if patisiran works in Phase 3. We are lowering our target price from $145 to $50 and maintaining our Outperform rating on Alnylam. We have removed FAC from our model. We have lowered probability of success for other earlier programs. New probability of success for hemophilia and porphyria are 20% and 10% vs. old assumptions of 65% and 25% (respectively). Though patisiran is a different technology for different disease, we are adjusting our assumptions as we see greater risk on clinical success and peak sales. We lowered our POS on FAP to 80% from 100% and lowered peak sales by $200M (or 10% lower market share at peak). We are maintaining our Outperform rating since we think Phase 3 patisiran still has a reasonable shot of working mid-17 and the PCSK9 readout may be positive in November."

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $70.30 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Credit Suisse

Add Your Comment